Monopar Therapeutics (MNPR) Competitors $37.49 +2.60 (+7.45%) Closing price 04/14/2025 04:00 PM EasternExtended Trading$36.37 -1.12 (-2.99%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. PHVS, XERS, NTLA, EOLS, AVDL, CRON, PRAX, OCS, CDXC, and NUVBShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Pharvaris (PHVS), Xeris Biopharma (XERS), Intellia Therapeutics (NTLA), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), Praxis Precision Medicines (PRAX), Oculis (OCS), ChromaDex (CDXC), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Pharvaris Xeris Biopharma Intellia Therapeutics Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Oculis ChromaDex Nuvation Bio Pharvaris (NASDAQ:PHVS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Which has stronger valuation & earnings, PHVS or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$2.68-4.71Monopar TherapeuticsN/AN/A-$8.40M-$3.60-10.41 Which has more risk & volatility, PHVS or MNPR? Pharvaris has a beta of -2.84, meaning that its share price is 384% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Do institutionals & insiders hold more shares of PHVS or MNPR? 1.8% of Monopar Therapeutics shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor PHVS or MNPR? In the previous week, Pharvaris had 16 more articles in the media than Monopar Therapeutics. MarketBeat recorded 19 mentions for Pharvaris and 3 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.86 beat Pharvaris' score of 0.39 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PHVS or MNPR more profitable? Pharvaris' return on equity of -38.52% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Monopar Therapeutics N/A -107.21%-87.57% Do analysts recommend PHVS or MNPR? Pharvaris presently has a consensus target price of $40.50, indicating a potential upside of 220.92%. Monopar Therapeutics has a consensus target price of $55.33, indicating a potential upside of 47.59%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community prefer PHVS or MNPR? Monopar Therapeutics received 10 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 73.02% of users gave Monopar Therapeutics an outperform vote while only 66.67% of users gave Pharvaris an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes3666.67% Underperform Votes1833.33% Monopar TherapeuticsOutperform Votes4673.02% Underperform Votes1726.98% SummaryPharvaris beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.18M$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-19.036.7721.6517.78Price / SalesN/A228.59376.3294.47Price / CashN/A65.6738.1534.64Price / Book19.945.886.443.99Net Income-$8.40M$141.32M$3.20B$247.24M7 Day Performance29.77%5.18%6.67%5.84%1 Month Performance26.02%-12.93%-6.27%-5.78%1 Year Performance860.05%-14.85%8.56%-1.99% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.2854 of 5 stars$37.49+7.5%$55.33+47.6%+860.1%$229.18MN/A-19.0310Gap UpPHVSPharvaris1.4014 of 5 stars$13.21-7.5%$40.50+206.6%-42.4%$690.75MN/A-4.7230XERSXeris Biopharma4.3059 of 5 stars$4.41flat$6.10+38.3%+117.8%$678.88M$203.07M-9.80290Short Interest ↑Positive NewsGap DownHigh Trading VolumeNTLAIntellia Therapeutics4.3198 of 5 stars$6.54-1.4%$37.56+474.2%-69.1%$677.00M$57.88M-1.20600Gap DownHigh Trading VolumeEOLSEvolus3.5057 of 5 stars$10.24-4.2%$24.67+140.9%-15.1%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2354 of 5 stars$6.69-1.6%$19.88+197.1%-51.7%$646.45M$169.12M-8.4770Gap DownCRONCronos Group1.5736 of 5 stars$1.68-1.8%$3.00+78.6%-31.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9121 of 5 stars$31.53-3.4%$123.33+291.2%-46.1%$635.74M$8.55M-3.06110Gap DownOCSOculis1.9659 of 5 stars$14.37-7.3%$29.50+105.3%+43.5%$627.42M$980,000.00-7.452High Trading VolumeCDXCChromaDex2.2642 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastNUVBNuvation Bio2.4461 of 5 stars$1.81+8.7%$8.75+384.8%-31.8%$611.32M$7.87M-0.8360News CoverageGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Pharvaris Alternatives Xeris Biopharma Alternatives Intellia Therapeutics Alternatives Evolus Alternatives Avadel Pharmaceuticals Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Oculis Alternatives ChromaDex Alternatives Nuvation Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
